Skip to main content
Top
Published in: Gastric Cancer 1/2016

01-01-2016 | Original Article

Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer

Authors: Mi-die Xu, Lei Dong, Peng Qi, Wei-wei Weng, Xiao-han Shen, Shu-juan Ni, Dan Huang, Cong Tan, Wei-qi Sheng, Xiao-yan Zhou, Xiang Du

Published in: Gastric Cancer | Issue 1/2016

Login to get access

Abstract

Background

Pituitary tumor-transforming gene-1 (PTTG1) is a transcription factor that can affect transcriptional activity, angiogenesis, and cell senescence. We examined PTTG1 mRNA and protein expression in gastric cancer (GC) cell lines and tissues to determine its value as a biomarker for GC diagnosis and therapy.

Methods

PTTG1 mRNA expression from 78 GC cases and paired adjacent normal mucosa (PCR cohort) as well as from five gastric cell lines was assessed using qRT-PCR. Nuclear and cytoplasmic RNA were extracted from two gastric cell lines to determine PTTG1 mRNA localization. PTTG1 protein expression from 98 GC cases, their paired adjacent normal mucosa, and 23 gastric intraepithelial neoplasia (GIN) cases was examined using immunohistochemistry (IHC cohort). The correlation between PTTG1 mRNA and protein expression and GC clinicopathological parameters was analyzed.

Results

PTTG1 mRNA expression in GC tissues and cell lines was significantly increased compared with adjacent normal gastric mucosa and normal gastric mucous cell lines (p < 0.05). PTTG1 expression was nuclear and cytoplasmic, with higher cytoplasmic expression. PTTG1 immunostaining significantly differed in GC (95.66 ± 20.65), GIN (84.00 ± 34.16), and normal adjacent mucosa (28 ± 22.25) (p < 0.001). Multivariate Cox regression analysis revealed that PTTG1 mRNA and protein expression are independent prognostic factors for GC patient survival.

Conclusion

Our results suggest that PTTG1 is a promising target for GC diagnosis and therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRef Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRef
2.
go back to reference De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18(suppl 6):vi120–vi123 De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18(suppl 6):vi120–vi123
3.
go back to reference Malik MT, Kakar SS. Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer. 2006;5:61.PubMedPubMedCentralCrossRef Malik MT, Kakar SS. Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer. 2006;5:61.PubMedPubMedCentralCrossRef
4.
go back to reference Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer. 2008;15(3):721–43.PubMedCrossRef Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer. 2008;15(3):721–43.PubMedCrossRef
5.
go back to reference Xie K, Wei D, Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev. 2006;17(3):147–56.PubMedCrossRef Xie K, Wei D, Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev. 2006;17(3):147–56.PubMedCrossRef
6.
go back to reference Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11(4):433–41.PubMedCrossRef Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11(4):433–41.PubMedCrossRef
7.
go back to reference Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84(2):761–7.PubMedCrossRef Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84(2):761–7.PubMedCrossRef
9.
go back to reference Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000;355(9205):716–9.PubMedCrossRef Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000;355(9205):716–9.PubMedCrossRef
10.
go back to reference Rehfeld N, Geddert H, Atamna A, Rohrbeck A, Garcia G, Kliszewski S, Neukirchen J, Bruns I, Steidl U, Fenk R, et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog. 2006;5:4.PubMedPubMedCentralCrossRef Rehfeld N, Geddert H, Atamna A, Rohrbeck A, Garcia G, Kliszewski S, Neukirchen J, Bruns I, Steidl U, Fenk R, et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog. 2006;5:4.PubMedPubMedCentralCrossRef
11.
go back to reference Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2009;42(2):87–103.PubMedCrossRef Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2009;42(2):87–103.PubMedCrossRef
12.
go back to reference Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S, Mount D, Bussey KJ. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery (St. Louis). 2013;154(6):1405–16.CrossRef Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S, Mount D, Bussey KJ. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery (St. Louis). 2013;154(6):1405–16.CrossRef
13.
go back to reference Pierconti F, Milardi D, Martini M, Grande G, Cenci T, Gulino G, Larocca LM, Rindi G, Pontecorvi A, De Marinis L. Pituitary-tumour-transforming-gene 1 expression in testicular cancer. Andrologia 2014. doi:10.1111/and.12283 Pierconti F, Milardi D, Martini M, Grande G, Cenci T, Gulino G, Larocca LM, Rindi G, Pontecorvi A, De Marinis L. Pituitary-tumour-transforming-gene 1 expression in testicular cancer. Andrologia 2014. doi:10.​1111/​and.​12283
14.
go back to reference Luo Z, Li B, Chen J, Ma Y, Tao H. Expression and the clinical significance of hPTTG1 in gastric cancer. Mol Med Rep. 2013;7(1):43–6.PubMed Luo Z, Li B, Chen J, Ma Y, Tao H. Expression and the clinical significance of hPTTG1 in gastric cancer. Mol Med Rep. 2013;7(1):43–6.PubMed
15.
go back to reference Wen CY, Nakayama T, Wang AP, Nakashima M, Ding YT, Ito M, Ishibashi H, Matsuu M, Shichijo K, Sekine I. Expression of pituitary tumor transforming gene in human gastric carcinoma. World J Gastroenterol. 2004;10(4):481–3.PubMedCrossRef Wen CY, Nakayama T, Wang AP, Nakashima M, Ding YT, Ito M, Ishibashi H, Matsuu M, Shichijo K, Sekine I. Expression of pituitary tumor transforming gene in human gastric carcinoma. World J Gastroenterol. 2004;10(4):481–3.PubMedCrossRef
16.
go back to reference Yamada M, Asanuma K, Yagihashi A, Nakamura M, Kameshima H, Kobayashi D, Watanabe N. Human pituitary tumor transforming gene 1 (hPTTG1) in gastric mucosal tissues. Am J Gastroenterol. 2001;96(4):1313–4.PubMedCrossRef Yamada M, Asanuma K, Yagihashi A, Nakamura M, Kameshima H, Kobayashi D, Watanabe N. Human pituitary tumor transforming gene 1 (hPTTG1) in gastric mucosal tissues. Am J Gastroenterol. 2001;96(4):1313–4.PubMedCrossRef
17.
go back to reference Lauwers GY, Franceschi S, Carneiro F, Montgomery E, Graham DY, Tatamatsu M, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, 4th edn. Lyon: IARC; 2010. pp 48–59 Lauwers GY, Franceschi S, Carneiro F, Montgomery E, Graham DY, Tatamatsu M, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, 4th edn. Lyon: IARC; 2010. pp 48–59
18.
go back to reference Lauren P. The two histological main types of gastric carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed Lauren P. The two histological main types of gastric carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
19.
go back to reference Edge SBD, Compton C. AJCC cancer staging manual. New York: Springer; 2010. Edge SBD, Compton C. AJCC cancer staging manual. New York: Springer; 2010.
20.
go back to reference Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, Zhou XY, Du X. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med. 2013;11(1):122.PubMedPubMedCentralCrossRef Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, Zhou XY, Du X. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med. 2013;11(1):122.PubMedPubMedCentralCrossRef
21.
go back to reference Thike AA, Chng MJ, Fook-Chong S, Tan PH. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001;33(1):21–5.PubMed Thike AA, Chng MJ, Fook-Chong S, Tan PH. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001;33(1):21–5.PubMed
22.
go back to reference Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285(5426):418–22.PubMedCrossRef Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285(5426):418–22.PubMedCrossRef
23.
go back to reference Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang Q, Wang Y, Lu N, He S, Zhan Q, et al. PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 2009;69(8):3283–90.PubMedCrossRef Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang Q, Wang Y, Lu N, He S, Zhan Q, et al. PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 2009;69(8):3283–90.PubMedCrossRef
24.
go back to reference Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci USA. 2014;111(3):1008–13.PubMedPubMedCentralCrossRef Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci USA. 2014;111(3):1008–13.PubMedPubMedCentralCrossRef
25.
go back to reference Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol. 2009;43(5):179–85.PubMedCrossRef Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol. 2009;43(5):179–85.PubMedCrossRef
26.
go back to reference Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis (Oxf). 2007;28(3):749–59.CrossRef Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis (Oxf). 2007;28(3):749–59.CrossRef
27.
go back to reference Akino K, Akita S, Mizuguchi T, Takumi I, Yu R, Wang XY, Rozga J, Demetriou AA, Melmed S, Ohtsuru A, et al. A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res. 2005;129(1):142–6.PubMedCrossRef Akino K, Akita S, Mizuguchi T, Takumi I, Yu R, Wang XY, Rozga J, Demetriou AA, Melmed S, Ohtsuru A, et al. A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res. 2005;129(1):142–6.PubMedCrossRef
28.
go back to reference Chien W, Pei L. A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem. 2000;275(25):19422–7.PubMedCrossRef Chien W, Pei L. A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem. 2000;275(25):19422–7.PubMedCrossRef
29.
go back to reference Pei L. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem. 2000;275(40):31191–8.PubMedCrossRef Pei L. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem. 2000;275(40):31191–8.PubMedCrossRef
30.
go back to reference Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast. 2004;13(1):80–1.PubMedCrossRef Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast. 2004;13(1):80–1.PubMedCrossRef
31.
go back to reference Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, Petillo D, Ooi A, Anema J, Lane B, et al. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res. 2012;72(17):4361–71.PubMedCrossRef Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, Petillo D, Ooi A, Anema J, Lane B, et al. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res. 2012;72(17):4361–71.PubMedCrossRef
Metadata
Title
Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer
Authors
Mi-die Xu
Lei Dong
Peng Qi
Wei-wei Weng
Xiao-han Shen
Shu-juan Ni
Dan Huang
Cong Tan
Wei-qi Sheng
Xiao-yan Zhou
Xiang Du
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 1/2016
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-015-0459-2

Other articles of this Issue 1/2016

Gastric Cancer 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.